Compare Clorox Co (CLX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs TG Therapeutics Inc — how do they compare? Clorox Co trades at $108.39 (market cap $13.09B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Clorox Co is the larger of the two by market cap, and Clorox Co pays a 4.62% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CLX | TGTX | |
|---|---|---|
Market Cap | $13.09B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $59.06 |
52-Week Low | $86.12 | $26.94 |
Enterprise Value | $18.47B | $7.84B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.69, down 1.87% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Recent Q4 2026 earnings beat expectations with EPS of $1.66 versus $1.64 estimated, though revenue trends remain pressured by inflation and consumer value-seeking. The company increased its quarterly dividend to $1.25 per share, signaling confidence in cash flow stability.
Outlook is cautious amid margin pressures and competitive threats, with Wall Street largely neutral (69% hold rating). The consensus price target of $97.50 suggests limited upside from current levels, while debt-to-asset ratio rising to 66.4% in 2026 highlights balance sheet risks. Investment appeal hinges on successful cost management and category recovery.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
